Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
Adaptive Biotechnologies reported financial results for Q4 and full year 2022, revealing a 20% revenue growth year-over-year, totaling $185.3 million. Q4 revenue reached $55.2 million, a 46% increase from Q4 2021. Key drivers included a 70% surge in MRD revenue and a 54% increase in clonoSEQ test volume. Operating expenses decreased by 5% to $94.4 million, with a net loss of $40.2 million. For 2023, the company aims for revenue between $205 million and $215 million and plans to lower operating expenses. With $498.2 million in cash reserves, Adaptive is positioned for sustainable growth.
- Revenue growth of 20% year-over-year, totaling $185.3 million.
- Q4 revenue at $55.2 million, a 46% increase from Q4 2021.
- MRD revenue increased by 70% to $28.1 million in Q4 2022.
- Cash reserves of $498.2 million facilitating sustainable growth.
- Long-term guidance of 20%-30% revenue CAGR.
- Net loss of $200.4 million for 2022, though improved from $207.3 million in 2021.
- Operating expenses up 6% year-over-year to $385.5 million.
SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2022.
“We finished the year with
Recent Highlights
- Revenue of
$55.2 million for the fourth quarter and$185.3 million for the full year of 2022, representing a46% increase and20% increase over the corresponding periods in 2021, respectively. - clonoSEQ test volume increased
54% to 10,526 tests delivered in the fourth quarter of 2022, compared to the fourth quarter 2021 and ended the year with 36,871 tests delivered, up51% versus 2021. - Launched clonoSEQ to assess MRD in patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin’s lymphoma, with Medicare coverage.
- Delivered 2 additional TCR data packages to Genentech.
- Strengthened our capital position, ending the year with
$498.2 million in cash, cash equivalents and marketable securities. - Provided long-term guidance including a
20% -30% revenue CAGR, positive adjusted EBITDA in 2025 and cash flow breakeven in 2026.
Fourth Quarter 2022 Financial Results
Revenue was
Operating expenses were
Net loss was
Adjusted EBITDA (non-GAAP) was a loss of
Full Year 2022 Financial Results
Revenue was
Operating expenses for 2022 were
Net loss was
Adjusted EBITDA (non-GAAP) was a loss of
Cash, cash equivalents and marketable securities was
2023 Financial Guidance
Adaptive Biotechnologies expects full year 2023 revenue to be in the range of
We expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of
Management will provide further details on the 2023 outlook during the conference call.
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2022 financial results after market close on Tuesday, February 14, 2023 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Use of Non-GAAP Financial Measure
To supplement our unaudited consolidated statements of operations and unaudited consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, restructuring expense and share-based compensation expense. We have provided a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.
Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.
Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:
- all expenditures or future requirements for capital expenditures or contractual commitments;
- changes in our working capital needs;
- interest expense, which is an ongoing element of our costs to operate;
- income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;
- the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;
- the noncash component of employee compensation expense; and
- the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our March 2022 restructuring and reduction in workforce.
In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.
ADAPTIVE MEDIA
Erica Jones, Associate Director, Product Communications
206-279-2423
media@adaptivebiotech.com
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
| Adaptive Biotechnologies | ||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | $ | 55,198 | $ | 37,930 | $ | 185,308 | $ | 154,344 | ||||||||
| Operating expenses | ||||||||||||||||
| Cost of revenue | 16,589 | 14,356 | 57,909 | 49,301 | ||||||||||||
| Research and development | 31,222 | 34,699 | 141,756 | 142,343 | ||||||||||||
| Sales and marketing | 23,716 | 26,696 | 95,603 | 95,465 | ||||||||||||
| General and administrative | 22,428 | 23,346 | 88,527 | 74,502 | ||||||||||||
| Amortization of intangible assets | 429 | 429 | 1,699 | 1,699 | ||||||||||||
| Total operating expenses | 94,384 | 99,526 | 385,494 | 363,310 | ||||||||||||
| Loss from operations | (39,186 | ) | (61,596 | ) | (200,186 | ) | (208,966 | ) | ||||||||
| Interest and other income, net | 2,602 | 239 | 4,056 | 1,668 | ||||||||||||
| Interest expense | (3,585 | ) | — | (4,238 | ) | — | ||||||||||
| Net loss | (40,169 | ) | (61,357 | ) | (200,368 | ) | (207,298 | ) | ||||||||
| Add: Net loss attributable to noncontrolling interest | 41 | (76 | ) | 177 | 19 | |||||||||||
| Net loss attributable to Adaptive Biotechnologies Corporation | $ | (40,128 | ) | $ | (61,433 | ) | $ | (200,191 | ) | $ | (207,279 | ) | ||||
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | $ | (0.28 | ) | $ | (0.43 | ) | $ | (1.40 | ) | $ | (1.48 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | 143,054,722 | 141,228,918 | 142,515,917 | 140,354,915 | ||||||||||||
| Adaptive Biotechnologies | ||||||||
| Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| (unaudited) | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 90,030 | $ | 139,065 | ||||
| Short-term marketable securities (amortized cost of | 408,166 | 213,996 | ||||||
| Accounts receivable, net | 40,057 | 17,409 | ||||||
| Inventory | 14,453 | 19,263 | ||||||
| Prepaid expenses and other current assets | 9,440 | 13,015 | ||||||
| Total current assets | 562,146 | 402,748 | ||||||
| Long-term assets | ||||||||
| Property and equipment, net | 83,447 | 85,262 | ||||||
| Operating lease right-of-use assets | 80,763 | 87,678 | ||||||
| Long-term marketable securities (amortized cost of | — | 217,145 | ||||||
| Restricted cash | 2,398 | 2,138 | ||||||
| Intangible assets, net | 6,827 | 8,526 | ||||||
| Goodwill | 118,972 | 118,972 | ||||||
| Other assets | 2,064 | 875 | ||||||
| Total assets | $ | 856,617 | $ | 923,344 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 8,084 | $ | 3,307 | ||||
| Accrued liabilities | 12,424 | 9,343 | ||||||
| Accrued compensation and benefits | 15,935 | 15,642 | ||||||
| Current portion of operating lease liabilities | 9,230 | 5,055 | ||||||
| Current portion of deferred revenue | 64,115 | 80,460 | ||||||
| Total current liabilities | 109,788 | 113,807 | ||||||
| Long-term liabilities | ||||||||
| Operating lease liabilities, less current portion | 98,772 | 106,685 | ||||||
| Deferred revenue, less current portion | 58,599 | 98,750 | ||||||
| Revenue interest liability, net | 125,360 | — | ||||||
| Total liabilities | 392,519 | 319,242 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Preferred stock: | — | — | ||||||
| Common stock: | 14 | 14 | ||||||
| Additional paid-in capital | 1,387,349 | 1,324,006 | ||||||
| Accumulated other comprehensive loss | (4,116 | ) | (1,137 | ) | ||||
| Accumulated deficit | (919,082 | ) | (718,891 | ) | ||||
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 464,165 | 603,992 | ||||||
| Noncontrolling interest | (67 | ) | 110 | |||||
| Total shareholders’ equity | 464,098 | 604,102 | ||||||
| Total liabilities and shareholders’ equity | $ | 856,617 | $ | 923,344 | ||||
Adjusted EBITDA
The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net loss attributable to Adaptive Biotechnologies Corporation | $ | (40,128 | ) | $ | (61,433 | ) | $ | (200,191 | ) | $ | (207,279 | ) | ||||
| Interest and other income, net | (2,602 | ) | (239 | ) | (4,056 | ) | (1,668 | ) | ||||||||
| Interest expense | 3,585 | — | 4,238 | — | ||||||||||||
| Depreciation and amortization expense | 5,286 | 4,849 | 20,920 | 13,953 | ||||||||||||
| Restructuring expense | — | — | 2,023 | — | ||||||||||||
| Share-based compensation expense | 14,294 | 11,875 | 55,477 | 43,251 | ||||||||||||
| Adjusted EBITDA | $ | (19,565 | ) | $ | (44,948 | ) | $ | (121,589 | ) | $ | (151,743 | ) | ||||
FAQ
What were Adaptive Biotechnologies' financial results for Q4 2022?
What is the revenue guidance for Adaptive Biotechnologies in 2023?
How much cash did Adaptive Biotechnologies have at the end of 2022?
What was the net loss for Adaptive Biotechnologies in 2022?
What were the key drivers of revenue growth for Adaptive Biotechnologies in 2022?
